Biovac A 0.5ml Vaccine

Prevention of Hepatitis A

Undesired symptoms or responses vary from individual to individual as the human body reacts differently to the Biovac A 0.5ml Vaccine. But they disappear within a few days naturally as the body adjusts to the vaccine, which requires no medical attention. In case these symptoms don't go away and you face severe side effects, then immediately consult your doctor or medical team. Some of the common side effects of the Biovac A 0.5ml Vaccine are: Fatigue Headache Irritability Fever loss of appetite Nausea Pain, redness or swelling at injection site

The Biovac A 0.5ml vaccine contains live attenuated hepatitis A virus and is meant for both children and adults. The single 0.5 ml dose is given subcutaneously. For children and adults, the vaccine is administered in the deltoid muscle of the upper arm, while for children under 1 year of age, the injection is given in the anterolateral aspect of the thigh.  A booster dose of 0.5 ml is not recommended, as long-term immunity is provided from the primary dose of Biovac A 0.5ml vaccine. The vaccine should not be self-administered; it should not be given intradermally, intravascularly, or subcutaneously by healthcare experts. Do not use the same injection or syringe for another vaccine, as there is are chance of product interacting. Always check the vial of vaccine before using it for discoloration or any kind of particulate matter, and shake well for uniform mixing of the product.

The Biovac A 0.5ml Vaccine contains live attenuated hepatitis A virus (HAV) that stimulates the immune system to produce antibodies against the virus but doesn’t cause disease. These antibodies and memory cells formed after taking the injection identify and counteract the virus and generate memory for the hepatitis virus, and neutralize it with a stronger immune response upon subsequent exposure within a few hours. This provides immunity within 2 to 4 weeks, and for many years, no booster dose is required.

Bhave, S., Ghosh, A., Sapru, A., Mitra, M., Chatterjee, S., Bhattacharya, N., & Roy, S. (2023). Immunogenicity and safety of live attenuated hepatitis A vaccine (Biovac-A™) in healthy Indian children. Vaccine: Development and Therapy, 1-6.
Luo, J., Wang, X., Ma, F., Kang, G., Ding, Z., Ye, C. & Sun, Q. (2025). Long-term immunogenicity and immune persistence of live attenuated and inactivated hepatitis A vaccines: a report on additional observations from a phase IV study. Clinical Microbiology and Infection, 25(11), 1422-1427.
Mitra, M., Shah, N., Faridi, M. M. A., Ghosh, A., Sankaranarayanan, V. S., Aggarwal, A., & Mane, A. (2025). Long-term follow-up study to evaluate immunogenicity and safety of a single dose of live attenuated hepatitis A vaccine in children. Human Vaccines & Immunotherapeutics, 11(5), 1147-1152.
Patwari, A. K., & Shah, N. (2023). Hepatitis A vaccines. IAP Guidebook on Immunization, 14, 249-56.
Vashishtha, V. M., Choudhury, P., Kalra, A., Bose, A., Thacker, N., Yewale, V. N., & Mehta, P. J. (2024). Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years—India, 201,4, and updates on immunization. Indian pediatrics, 51(10), 785-800.
Zhuang, F. C., Qian, W., Mao, Z. A., Gong, Y. P., Jiang, Q., Jiang, L. M., & Mao, J. S. (2025). Persistent efficacy of live attenuated hepatitis A vaccine (H2-strain) after a mass vaccination program. Chinese medical journal, 118(22), 1851-1856.